Sanofi is teaming up with Abbott while Medtronic will work with Novo Nordisk on integrating their diabetes platforms in the latest examples of technological convergence.
The companies said they wiill work to integrate their glucose sensing and insulin delivery technologies with the goal of simplifying how people manage their diabetes.
In a statement, Medtronic said the integration means people with diabetes and their healthcare professionals and caregivers will be able to automatically track these two important items in a single place.
Sanofi will develop new tools that combine its future treatment platforms with Abbott's FreeStyle Libre sensor-based glucose monitoring system. Novo Nordisk will work to integrate its insulin dosing data from smart insulin pens with continuous glucose monitoring devices from Medtronic.
In a statement, Sanofi said the 'non-exclusive collaboration' will initially enable data sharing, at the consent of the user, between Abbott’s FreeStyle Libre mobile app and cloud software and Sanofi’s connected insulin pens, apps and cloud software that are currently in development.
It said it is currently working to provide connected pens, apps and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools.
“For close to a century, Sanofi has been supporting those living with diabetes through our robust portfolio of medicines," said Gustavo Pesquin, senior vice president Global Diabetes and Cardiovascular Franchise at Sanofi.
"This strategic relationship with Abbott is representative of the next evolution of our commitment for better diabetes care by incorporating digital tools into the daily life of people living with diabetes.
“By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes.”
"As the global leader in continuous glucose monitoring, we see a significant opportunity to impact the health of millions of people living with diabetes by developing new tools and connectivity with Sanofi, a leader in the insulin space," said Jared Watkin, senior vice president, Diabetes Care, Abbott.